Omega-3 FFAs not effective for relapse prevention in Crohn disease
Are omega-3 free fatty acids useful in the prevention of relapse in Crohn disease?
Daily supplementation with omega-3 free fatty acids (FFAs) was no more effective than placebo in the prevention of relapse in Crohn disease. (LOE = )
Feagan BG, Sandborn WJ, Mittmann U, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease. The EPIC randomized controlled trials. JAMA 2008;299:1690-1697. [PMID:18398081]
Randomized controlled trial (double-blinded)
Because of their anti-inflammatory effects omega-3 FFAs may be useful in the treatment of Crohn disease. These investigators, in 2 separate studies, randomized 363 patients (in study 1) and 375 patients (in study 2) with Crohn disease in a double-blind fashion (concealed allocation assignment) to receive four 1-g gelatin capsules of omega-3 FFAs or identical placebo daily for at least 52 weeks. Eligible patients included adults with confirmed Crohn disease and a score of less than 150 points on the previously validated Crohn Disease Activity Index (CDAI), consistent with disease remission for at least 3 months but not longer than 12 months. Individuals assessing outcomes remained masked to treatment group assignment. Complete follow-up occurred for 98% of patients for 1 year. Using intention-to-treat analysis, clinical relapse (defined as a CDAI score of 150 points or more and at least a 70-point increase from baseline value) occurred at a similar rate in both treatment groups of study 1 and study 2 (31.6% vs 35.7%; 47.8% vs 48.8%, respectively). Both studies were 80% powered to detect a 15% difference in relapse rates. No significant differences in adverse events were reported between the treatment groups.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.